Pure Global AI
NCT06259084Not yet recruiting

Study to Estimate Seedchrony's Predictive Capacity in the Success of Embryo Implantation.

Study to Detect the Predictive Capacity of a Composite Biological Marker in the Success of Embryonic Implantation in Fertilization Treatments In Vitro (IVF): Seedchrony Pilot.
Manina MedtechClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Infertility
Drug/Device/Intervention
Seedchrony
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Manina Medtech
Timeline & enrollment
Phase
N/A
Start date
Feb 05, 2024
End date
Apr 05, 2025
Enrollment
80 participants
Primary outcome

Intrauterine biomarker concentration on the day before embryo transfer,Intrauterine biomarker concentration on the embryo transfer day

Summary

In Vitro Fertilization (IVF) success is below 40%, with Embryo Transfer the leading cause of
 IVF failure. This clinical investigation aims to evaluate if the levels of an intrauterine
 biomarker dissolved in the uterine fluid (alone or as a complex biological marker) can
 predict the outcome of embryo transfer.

ICD-10 classifications
Female infertilityMale infertilityFemale infertility, unspecifiedFemale infertility of other originFemale infertility of uterine origin
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06259084
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06259084 through Pure Global AI's free database. This phase not specified trial is sponsored by Manina Medtech and is currently Not yet recruiting. The study focuses on Infertility. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.